Skip to main content
Midas Edge

Burning Rock Biotech Ltd

For the period ended Sep 8, 2025. Filed Sep 8, 2025.

View on SEC.gov

About this filing

What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.

Sep 8, 2025 · Filed Sep 8, 2025

Use the contents to explore the available documents and sections.

BNR$13.42+1.3%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · Selected Financial Data

Selected Financial Data

For the three months ended
RevenuesJune 30,2024September 30,2024December 31,2024March 31,2025June 30,2025
(RMB in thousands)
Central laboratory channel48,77339,98439,27838,29640,861
In-hospital channel59,87263,76943,46457,68762,496
Pharma research and development channel26,88824,89143,28037,09945,197
Total revenues135,533128,644126,022133,082148,554
For the three months ended
Gross profitJune 30,2024September 30,2024December 31,2024March 31,2025June 30,2025
(RMB in thousands)
Central laboratory channel38,42433,26233,15332,19135,937
In-hospital channel44,05846,58029,56343,89546,490
Pharma research and development channel12,95612,00426,70621,31525,676
Total gross profit95,43891,84689,42297,401108,103
For the three months ended
Share-based compensation expensesJune 30,2024September 30,2024December 31,2024March 31,2025June 30,2025
(RMB in thousands)
Cost of revenues464289520308280
Research and development expenses12,0083,1803,2021,800(270)
Selling and marketing expenses1,2321,9171,3531,025364
General and administrative expenses54,4074,7322,9371,4132,005
Total share-based compensation expenses68,11110,1188,0124,5462,379
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.